A5002366090- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Immune Cell Function and Interaction
- Virus-based gene therapy research
- Lymphoma Diagnosis and Treatment
- Immunotherapy and Immune Responses
- Immunodeficiency and Autoimmune Disorders
- T-cell and B-cell Immunology
- Chronic Lymphocytic Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Viral-associated cancers and disorders
- Acute Myeloid Leukemia Research
- Blood disorders and treatments
- Cytomegalovirus and herpesvirus research
- Renal and related cancers
- Acute Lymphoblastic Leukemia research
- CNS Lymphoma Diagnosis and Treatment
- CRISPR and Genetic Engineering
- Child and Adolescent Psychosocial and Emotional Development
- Nanowire Synthesis and Applications
- Childhood Cancer Survivors' Quality of Life
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Renal Transplantation Outcomes and Treatments
- Pancreatic and Hepatic Oncology Research
University College London
2016-2025
Royal Free London NHS Foundation Trust
2013-2025
University College London Hospitals NHS Foundation Trust
2014-2025
Royal London Hospital
2004-2025
James Madison University
2025
University of Oxford
2003-2024
The Royal Free Hospital
2013-2024
Toronto Metropolitan University
2021-2024
National Health Service
2011-2024
Institute of Infection and Immunity
2016-2024
CD28 and CTLA-4 (CD152) play essential roles in regulating T cell immunity, balancing the activation inhibition of responses, respectively. Although both receptors share same ligands, CD80 CD86, specific requirement for two distinct ligands remains obscure. In present study, we demonstrate that, although targets CD86 destruction via transendocytosis, this process results separate fates itself. presence CD80, remained ligand bound, was ubiquitylated trafficked late endosomes lysosomes....
Abstract Patients with Wiskott–Aldrich syndrome (WAS) lacking a human leukocyte antigen-matched donor may benefit from gene therapy through the provision of gene-corrected, autologous hematopoietic stem/progenitor cells. Here, we present comprehensive, long-term follow-up results (median follow-up, 7.6 years) (phase I/II trial no. NCT02333760 ) for eight patients WAS having undergone phase lentiviral vector-based trials (nos. NCT01347346 and NCT01347242 ), focus on thrombocytopenia...
STAT6 (signal transducer and activator of transcription 6) is a factor that plays central role in the pathophysiology allergic inflammation. We have identified 16 patients from 10 families spanning three continents with profound phenotype early-life onset immune dysregulation, widespread treatment-resistant atopic dermatitis, hypereosinophilia esosinophilic gastrointestinal disease, asthma, elevated serum IgE, IgE-mediated food allergies, anaphylaxis. The cases were either sporadic (seven...
The role of allogeneic transplantation with reduced-intensity conditioning in diffuse large B-cell lymphoma (DLBCL) is currently unclear, relatively little published data. We report the outcome (RIT) a cohort 48 consecutive patients relapsed/refractory DLBCL (30 de novo disease and 18 transformed follicular lymphoma) who underwent an alemtuzumab-containing regimen, median follow-up 52 months.Patients had experienced treatment failure five lines prior therapy, including autologous 69%, 17%...
Background.A retrospective study of the clinical, epidemiologic, and virologic features norovirus gastroenteritis in 12 adult allogeneic hematopoietic stem cell transplant (HSCT) recipients.
Follicular lymphoma (FL) is an indolent disorder that treatable but considered incurable with chemotherapy alone. The curative potential of allogeneic transplantation using conventional myeloablative conditioning has been demonstrated, this approach precluded in the majority patients FL because excessive toxicity. Thus, reduced-intensity regimens are being explored.This study reports outcome 82 consecutive who underwent fludarabine, melphalan, and alemtuzumab for vivo T-cell depletion....
Purpose Reduced-intensity conditioning has minimized nonrelapse-related mortality rates after allogeneic transplantation in patients with Hodgkin's lymphoma, and relapse now become the major cause for treatment failure. We aimed to assess impact of donor lymphocyte infusions (DLIs) on incidence when administered mixed chimerism their utility as salvage therapy given relapse. Patients Methods This study reports outcomes 76 consecutive multiply relapsed or refractory lymphoma who underwent...
Haematology patients receiving chemo- or immunotherapy are considered to be at greater risk of COVID-19-related morbidity and mortality. We aimed identify factors for COVID-19 severity assess outcomes in where complicated the treatment their haematological disorder. A retrospective cohort study was conducted 55 with disorders COVID-19, including 52 malignancy, two bone marrow failure one immune-mediated thrombotic thrombocytopenic purpura (TTP). diagnosis coincided a new malignancy four...
Reduced-intensity allogeneic stem cell transplantation (RIC-AlloSCT) is being increasingly considered for patients with aggressive lymphoma, but limited evidence exists in mantle lymphoma (MCL). We report a retrospective study of transplant outcomes RIC-AlloSCT MCL 70 (median age, 48 years, range: 30-67 years), 57 receiving an Alemtuzumab-containing regimen. Thirty-four percent had received prior autologous transplant. The 1- and 5-year nonrelapse mortality (NRM) was 18% (95% confidence...